Title: Gliclazide
CAS Registry Number: 21187-98-4
CAS Name: N-[[(Hexahydrocyclopenta[c]pyrrol-2(1H)-yl)amino]carbonyl]-4-methylbenzenesulfonamide
Additional Names: 1-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea; N-(4-methylbenzenesulfonyl)-N¢-(3-azabicyclo[3.3.0]oct-3-yl)urea; 1-(3-azabicyclo[3.3.0]oct-3-yl)-3-(p-tolylsulfonyl)urea
Manufacturers' Codes: S-1702
Trademarks: Diamicron (Servier); Glimicron (Dainippon); Nordialex (Pharmacodex)
Molecular Formula: C15H21N3O3S
Molecular Weight: 323.41
Percent Composition: C 55.71%, H 6.54%, N 12.99%, O 14.84%, S 9.91%
Literature References: Prepn: Beregi et al., FR 1510714 and US 3501495 (1968 and 1970, both to Sci. Union & Co.-Soc. Franc. Rech. Med.). Series of articles on pharmacology: Arzneim.-Forsch. 22, 1686-1695 (1972). Toxicity data: J. Duhault et al., ibid. 1682. Review of pharmacology, efficacy: B. Holmes et al., Drugs 27, 301 (1984).
Properties: Crystals from anhydrous ethanol, mp 180-182°. LD50 orally in mice: >3 g/kg (Duhault).
Melting point: mp 180-182°
Toxicity data: LD50 orally in mice: >3 g/kg (Duhault)
Therap-Cat: Antidiabetic.
Keywords: Antidiabetic; Sulfonylurea Derivatives.
Gliotoxin Glipizide Gliquidone Glisoxepid Globin

Gliclazide ball-and-stick.png
Systematic (IUPAC) name
Clinical data
AHFS/ Micromedex Detailed Consumer Information
Legal status  ?
Pharmacokinetic data
Half-life 10.4 hours
CAS number 21187-98-4 YesY
ATC code A10BB09
PubChem CID 3475
DrugBank DB01120
ChemSpider 3356 YesY
KEGG D01599 YesY
ChEBI CHEBI:31654 YesY
Chemical data
Formula C15H21N3O3S 
Mol. mass 323.412 g/mol
 YesY (what is this?)  (verify)

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. Gliclazide is the research of SERVIER- A French Multinational. In India original Gliclazide is marketed in original Brand name as " Diamicron XR 60 " by SERVIER subsidiary SERDIA Pharmaceuticals, while other companies promote copies are "Glizid" , Glyloc and Reclide in India . In the Philippines, Servier markets it as Diamicron MR, like in most countries across the world. Many generic equivalents are also available e.g. Glubitor-OD, Clizid. It is not marketed in the United States. A modified-release formulation is also marketed. Its classification has been ambiguous, as literature uses it as both a first-generation [1] and second-generation[2] sulfonylurea. Gliclazide was proven to protect human pancreatic beta-cells from hyperglycemia-induced apoptosis.[3] It was also shown to have an antiatherogenic effect (preventing accumultaion of fat in arteries) in type 2 diabetes.[4]